Difference between revisions of "POEMS syndrome"
Jump to navigation
Jump to search
m |
m |
||
Line 3: | Line 3: | ||
|- | |- | ||
|style="background-color:#F0F0F0"|[[File:Headshot Cowan.jpg|frameless|upright=0.3|center]] | |style="background-color:#F0F0F0"|[[File:Headshot Cowan.jpg|frameless|upright=0.3|center]] | ||
− | |<big>[[User:Andrewc072|Andrew J. Cowan, MD]]<br> | + | |<big>[[User:Andrewc072|Andrew J. Cowan, MD]]<br>University of Washington<br>Seattle, WA</big><br>[https://www.linkedin.com/in/andrew-cowan-63b3a130/ LinkedIn] |
|- | |- | ||
|} | |} |
Revision as of 17:23, 27 February 2019
Section editor | |
---|---|
Andrew J. Cowan, MD University of Washington Seattle, WA |
POEMS: Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, and Skin changes
1 regimens on this page
1 variants on this page
|
Guidelines
EMN
- 2018: Gavriatopoulou et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias PubMed
All lines of therapy
RD
back to top |
RD: Revlimid (Lenalidomide) & Dexamethasone
Regimen
Study | Evidence |
---|---|
Nozza et al. 2017 | Phase II, <20 pts |
Chemotherapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
- Dexamethasone (Decadron) 40 mg PO once per week
Supportive medications
- Aspirin 100 mg PO once per day
- LMWH in "intolerant" patients
- Cotrimoxazole 800 mg PO twice per day two days per week
Monthly cycles, continued until progression or excess toxicity
References
- Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. link to original article contains verified protocol PubMed